Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer's disease (AD) is an age-related multifactorial neurodegenerative disorder.
Why it matters
This review notes that Alzheimer's genetics involves multiple genetic components rather than a single factor, and that non-European populations are underrepresented in prior studies. It does not report a treatment or cure, but points to the need for more diverse genetic research.
-
Obesity is a growing worldwide health problem, affecting many people due to excessive saturated fat consumption, lack of exercise, or a sedentary lifestyle.
Why it matters
This review discusses leptin resistance mechanisms that could be implicated in increasing the risk of developing Alzheimer's disease, since leptin resistance is frequently associated with obesity and obesity is considered a risk factor for Alzheimer's disease. It notes that some data are controversial and that further investigation is needed, so it offers no treatment or cure.
-
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia.
Why it matters
This review describes progress in developing blood, plasma, and eye biomarkers that might help diagnose Alzheimer's disease at an early stage. It concerns diagnosis and reports no treatment, cure, or prevention.
-
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Why it matters
Second-generation anti-amyloid monoclonal antibodies lower CNS amyloid burden but carry a significant risk of amyloid-related imaging abnormalities (ARIA), the most common side effect of this drug class. ARIA is usually asymptomatic but can cause symptoms and has been linked to one fatality with aducanumab and one with donanemab.
-
This study aims to quantify microglial activation in individuals with Alzheimer disease (AD) using the 18-kDa translocator protein (TSPO) PET imaging in the hippocampus and precuneus, the 2 AD-vulnerable regions, and to evaluate the association of baseline neuroinflammation with amyloidosis, tau, and longitudinal cognitive decline.
Why it matters
In 24 participants, baseline microglial activation measured with a TSPO PET tracer correlated with brain amyloidosis and longitudinal cognitive decline. This is a small observational imaging study and does not test any treatment targeting microglial activation.
-
18 F-SMBT-1 yielded high-contrast images at steady state (60-80 min after injection).
Why it matters
Using the tracer 18F-SMBT-1, binding was significantly higher in several cortical regions in the amyloid-positive Alzheimer disease group and also in the amyloid-positive cognitively normal group compared with amyloid-negative cognitively normal people. This is a cross-sectional PET study of reactive astrogliosis across the Alzheimer disease spectrum, not a treatment, cure or prevention.
-
Dementia is the clinical syndrome characterized by progressive loss of cognitive and emotional abilities to a degree severe enough to interfere with daily functioning.
Why it matters
This study compared machine-learning methods for classifying EEG signals from people with Alzheimer's disease versus frontotemporal dementia, reaching 78.5% and 86.3% accuracy. It is a diagnostic classification study and does not test any treatment, cure, or prevention.
-
Genome-wide association studies have led to numerous genetic loci associated with Alzheimer's disease (AD).
Why it matters
Using whole-genome sequencing in families with multiple Alzheimer's cases, this study identified 13 new candidate genes, many related to synaptic function and neuronal development. These are genetic associations that may guide future research, not a treatment or cure.
-
Applying an integrative multi-omics approach we report novel molecular and pathways alterations associated with AD pathology.
Why it matters
This multi-omics study of cerebrospinal fluid in older adults identified five major dimensions of heterogeneity associated with Alzheimer's disease and found overrepresentation of hemostasis, immune response and extracellular matrix signaling pathways. The work identifies molecular patterns and pathways that may relate to disease pathology, but it does not test any treatment or show a way to prevent or cure the disease.
-
50/100
There is a dearth of studies on the genetics of AD in the Arab world.
Why it matters
Reviewing 18 studies of Alzheimer's genetics in Arab populations, covering 2,173 people, this systematic review found 27 variants in 8 genes associated with Alzheimer's, 17 of them unique to Arab populations. The authors highlight how little genetic research on Alzheimer's exists in the Arab world and suggest Arab patients may have distinctive genetic and clinical susceptibility profiles.
-
Oculomotor behavior can provide insight into the integrity of widespread cortical networks, which may contribute to the differential diagnosis between Alzheimer's disease and frontotemporal dementia.
Why it matters
In 93 subjects, eye-tracking measures showed different oculomotor patterns in Alzheimer's disease, behavioral variant frontotemporal dementia and semantic variant primary progressive aphasia, which may help tell these conditions apart. This concerns diagnosis and does not test any treatment, cure or prevention.
-
Our findings lend support to a model in which fibrillar Aβ is still accumulating in the early stages of clinical disease but approaching a relative plateau, a point at which Aβ may uncouple from neurodegenerative processes including synaptic loss.
-
Clinical Alzheimer's disease (AD) trials currently face a critical shortfall of thousands of eligible participants, which inflates the duration and cost of the clinical study as well as threatens the scientific merit of promising clinical interventions.
Why it matters
This narrative review describes recruitment barriers that keep underrepresented minorities out of Alzheimer's disease clinical trials, which threatens the generalizability of findings. It is about trial recruitment and does not test any treatment, cure or prevention.
-
This study aimed to investigate whether spicy food consumption is associated with cognition and cerebrospinal fluid (CSF) biomarkers of AD in the Chinese population.
Why it matters
This study investigated whether eating spicy food is associated with cognition and spinal fluid biomarkers of Alzheimer's disease in a Chinese population. It is an observational study and cannot show that spicy food causes or prevents Alzheimer's disease.
-
Variations in many genes linked to sporadic Alzheimer's disease (AD) show abundant expression in microglia, but relationships among these genes remain largely elusive.
Why it matters
Using human embryonic stem cell-derived microglia-like cells carrying Alzheimer's-linked variants in CD33, INPP5D, SORL1 and TREM2, the study found Alzheimer's-like expression signatures in SORL1 and TREM2 cells and up-regulation of APOE as a convergent node. This is a cell-based laboratory study, not a treatment in people, so it does not show how to treat, cure or prevent Alzheimer's.
-
50/100
Gut microbiota represents a diverse and dynamic population of microorganisms harboring the gastrointestinal tract, which influences the host health and disease.
Why it matters
This review describes the gut-brain axis and notes that aging alters gut microbial populations, which can lead to CNS disorders such as dementia, and discusses probiotic intervention. It reports no proven treatment, cure or prevention for Alzheimer's disease.
-
Alzheimer Disease (AD) is a neurodegenerative disease characterized by two neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular neurofibrillary tangles.
Why it matters
This review states that current Alzheimer drugs (donepezil, galantamine, rivastigmine and memantine) are only symptomatic with modest benefits, and that therapies targeting amyloid β have been the focus for almost 30 years. It also notes that highly promising drugs recently failed to show clinical benefits in phase III trials.
-
Associations of physical exercise with Alzheimer disease (AD) biomarkers and cognitive functioning have been observed cross-sectionally.
Why it matters
This longitudinal study asked whether people who exercised more at baseline showed less change over time in Alzheimer's biomarkers and cognition, and whether APOE or BDNF genotype changed that. It is observational, so it does not prove that exercise prevents or treats Alzheimer's disease.
-
Globally, 50 million people live with dementia, with Alzheimer disease (AD) being responsible for two-thirds of the total cases.
Why it matters
This review discusses cellular senescence as a possible mechanism converting normal ageing into neurodegeneration, including in neurons, astrocytes and microglia. It offers no treatment, cure or prevention.
-
Accumulating data suggest cerebrospinal fluid (CSF) neurogranin (Ng) as a potential biomarker for cognitive decline and neurodegeneration in Alzheimer disease (AD).
Why it matters
In the ADNI cohort, cerebrospinal fluid neurogranin rose with disease severity and was tested against core Alzheimer's biomarkers, brain atrophy, glucose metabolism and cognitive decline. It is a biomarker study, so it does not show a treatment, cure or prevention.
-
Alzheimer's disease (AD) is characterized by high heterogeneity in disease manifestation, progression and risk factors.
Why it matters
This position paper states that sex and gender differences affect cognitive decline, brain atrophy, risk factors, and diagnostic biomarkers in Alzheimer's disease. It notes these differences are seldom considered in clinical practice or trial design, so it calls for future studies rather than reporting a treatment.
-
Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer's.
Why it matters
This review states that the cause of most Alzheimer's cases remains unknown and that patients generally receive a standard drug regimen regardless of cause, which may not halt or reverse disease progression. It discusses proposed approaches such as gene therapy and immunotherapy, but these are described as strategies to manage the disease, not established cures or preventions.
-
Participants in the most disadvantaged neighborhoods (n = 156) were younger, more often female, and less often college-educated or white than those in less disadvantaged neighborhoods (n = 1963).
Why it matters
This study found that living in the most disadvantaged neighborhoods was associated with poorer performance on tests of executive function, verbal learning, and memory. It suggests that this geospatial measure of neighborhood disadvantage may be useful for exploring socially rooted risk mechanisms and prioritizing high-risk communities for research and intervention.
-
50/100
Relative to CN participants, Obj-SCD was associated with faster amyloid accumulation and selective vulnerability of entorhinal cortical thinning, whereas MCI was associated with faster entorhinal and hippocampal atrophy.
-
Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure.
Why it matters
This review says PET imaging of amyloid, tau, and microglial activation can discriminate people with Alzheimer's disease and mild cognitive impairment from healthy controls, but that no single technique or tracer can yet be recommended as an optimal biomarker. It describes imaging as promising for diagnosis and for monitoring disease progression, not as a treatment or cure.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Depressive symptom trajectories and associated risks among bereaved Alzheimer disease caregivers
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
- Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression
- A Deep Learning Approach for Automated Diagnosis and Multi-Class Classification of Alzheimer's Disease Stages Using Resting-State fMRI and Residual Neural Networks
- Classification of Alzheimer's Disease with and without Imagery using Gradient Boosted Machines and ResNet-50
- Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages
- Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
- A multimodal machine learning model for predicting dementia conversion in Alzheimer’s disease
- Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
- The risk of Alzheimer's disease and cognitive impairment characteristics in eight mental disorders: A UK Biobank observational study and Mendelian randomization analysis